Is SBRA a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Sabra Health Care REIT (SBRA) rests on Senior housing operating recovery: Sabra's managed senior housing portfolio is the main growth engine, with same-property cash NOI up roughly 14% year over year in Q1 2026 as occupancy and rents recover. Revenue (TTM) is ~$880M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. Whether SBRA is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Sabra Health Care REIT is a self-managed real estate investment trust that owns and invests in healthcare property, including skilled nursing and transitional care facilities, managed senior housing communities, behavioral health, and specialty hospitals, spread across the United States and Canada. Its portfolio mixes triple-net leases (where operators pay Sabra fixed rent) with managed senior housing under RIDEA-style structures that give Sabra direct exposure to the operating income of those communities, so a chunk of its results moves with occupancy and rate trends in senior living. The investment picture centers on income and demographics. Sabra pays a quarterly dividend of about $0.30 per share (roughly a 6% yield at a mid-teens stock price) and its results are recovering as senior housing occupancy and rates climb off pandemic lows, with same-property managed senior housing cash NOI up double digits year over year in early 2026. Against that, the company carries meaningful leverage and depends on the financial health of its operators, so it trades more like a yield-plus-modest-growth vehicle than a high-growth name.
What's the case for buying SBRA?
1. Senior housing operating recovery
Sabra's managed senior housing portfolio is the main growth engine, with same-property cash NOI up roughly 14% year over year in Q1 2026 as occupancy and rents recover. Management has guided to low-to-mid teens NOI growth in senior housing managed assets for 2026. Because Sabra takes operating exposure on these assets, continued occupancy gains flow more directly to earnings than fixed-rent leases do.
2. Investment pipeline and acquisitions
The company has been actively deploying capital, closing or committing over $400 million of investments year to date in 2026 at initial cash yields around 8%. Acquisitions of senior housing and skilled nursing assets plus selective development funding expand the earnings base. This external growth supplements the internal NOI recovery and supports the raised full-year outlook.
3. Aging-demographics demand tailwind
The 80-and-over US population is set to expand sharply as baby boomers age, structurally increasing demand for skilled nursing and senior living. Sabra is positioned across the acuity spectrum to capture this. This long-duration tailwind underpins the multi-year case for occupancy and rent growth across the portfolio.
4. Balance sheet repositioning
Sabra has trimmed leverage to roughly 4.8x net debt to EBITDA on a pro forma basis, holds about $1.2 billion of liquidity, and has no material debt maturities until 2028. It is also re-tenanting weaker operators, including transitioning its Avamere-leased properties largely to Cascadia Healthcare. A cleaner balance sheet and stronger operator roster reduce refinancing and credit risk.
What are the risks to SBRA?
Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. The re-tenanting of properties (such as the Avamere-to-Cascadia transition) carries execution risk during handover. As a REIT it is sensitive to interest rates, which affect both its borrowing costs and how income investors value its yield. Leverage remains meaningful for a healthcare landlord, and the dividend, while covered by cash flow today, depends on continued occupancy recovery. Competition from far larger peers for acquisitions can compress the yields Sabra earns on new deals.
How is SBRA valued? (as of July 2026)
Snapshot for SBRA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Market cap: ~$5.0B
- Revenue (TTM): ~$880M
- Normalized FFO/share (2026 guide): ~$1.53-$1.55
- Normalized AFFO/share (2026 guide): ~$1.59-$1.61
- Dividend yield: ~6%
- Net debt / EBITDA: ~4.8x
Sabra reported Q1 2026 revenue of about $222 million and normalized AFFO of roughly $0.39 per share, and management raised full-year 2026 guidance to call for mid-to-high single digit FFO and AFFO per share growth over 2025. On a REIT-appropriate basis the shares trade around 13 times forward FFO, which is a discount to larger senior-housing-focused peers. The quarterly dividend of about $0.30 represents a payout near 77% of normalized AFFO, leaving some cushion.
How do you decide if SBRA is a buy?
Rather than asking whether SBRA is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SBRA indirectly through an index or sector ETF before adding more.
For the full picture, see the SBRA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SBRA against your real portfolio and see your actual exposure before deciding.
The bottom line on SBRA
The bottom line: Sabra Health Care REIT's story right now is Senior housing operating recovery, with revenue (ttm) at ~$880M. If you believe that narrative continues, the call is about sizing SBRA sensibly and checking overlap with what you own; if you doubt it (the risk: sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on SBRA
- SBRA stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- SBRA stock forecast (the drivers and risks shaping the outlook)
- Does SBRA pay a dividend?
Build a basket around SBRA with Walnut
Use Sabra Health Care REIT as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is SBRA a good stock to buy right now?
+
The case for Sabra Health Care REIT right now is Senior housing operating recovery, with revenue (ttm) at ~$880M. If you believe that thesis holds, SBRA is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Sabra Health Care REIT do?
+
Sabra Health Care REIT is a self-managed real estate investment trust that owns and invests in healthcare property, including skilled nursing and transitional care facilities, mana
What are the main risks of SBRA?
+
Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. The re-tenanting of properties (such as the Avamere-to-Cascadia transition) carries execution risk during handover. As a REIT it is sensitive to interest rates, which affect both its borrowing costs and how income investors value its yield. Leverage remains meaningful for a healthcare landlord, and the dividend, while covered by cash flow today, depends on continued occupancy recovery. Competition from far larger peers for acquisitions can compress the yields Sabra earns on new deals.
What does Sabra Health Care REIT do?
+
Sabra owns and invests in healthcare real estate across the US and Canada, including skilled nursing and transitional care facilities, managed senior housing communities, behavioral health, and specialty hospitals. It earns money from rent on leased properties and from operating income on its managed senior housing assets.
Does SBRA pay a dividend?
+
Yes. Sabra pays a quarterly cash dividend of about $0.30 per share, or roughly $1.20 annually, which works out to a yield near 6% at a mid-teens-to-low-twenties share price. The 2026 payout was around 77% of normalized AFFO, leaving some coverage cushion.
Is SBRA a growth stock or an income stock?
+
It behaves mainly as an income stock. Investors generally hold it for the roughly 6% dividend yield, with modest per-share FFO growth (mid-to-high single digits guided for 2026) layered on top from senior housing recovery and acquisitions rather than rapid expansion.
How did Sabra perform in early 2026?
+
Sabra reported Q1 2026 revenue of about $222 million and normalized AFFO of roughly $0.39 per share, with same-property managed senior housing cash NOI up about 14% year over year. Management raised full-year 2026 guidance on the strength of the recovery and its investment pipeline.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell SBRA; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.